• Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

CONGRESOS

Nuestros médicos oncólogos e investigadores expertos del laboratorio son conferenciantes, a la vez que organizadores de muchos de los más importantes seminarios y reuniones científicas por todo el mundo.

Hemos presentado los resultados de nuestras investigaciones sobre las causas del cáncer y tratamientos novedosos se han presentado en los más importantes congresos nacionales e internacionales.

SELECCIONA UN AÑO PARA VER EL
HISTÓRICO DE CONGRESOS

IASLC 15th World Congress on Lung Cancer (WCLC)

FECHA27/10/2013 - 31/10/2013

LUGAR DE REALIZACIÓNSydney, Australia

The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) (NCT00617) Rosell R, MD, PhD

[volver]

24th International Congress on Anti-Cancer Treatment (ICACT)

FECHA05/02/2013 - 06/02/2013

LUGAR DE REALIZACIÓNParis, France

Understanding adaptive resistance in EGFR mutant NSCLC: Deconstructing the myth of T790M Rosell R, MD, PhD

Molecular based decision making for personalized cancer management Rosell R, MD, PhD

[volver]

37th Congress of the European Society of Medical Oncology

FECHA28/09/2012 - 02/10/2012

LUGAR DE REALIZACIÓNVienna, Austria

Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR exon 19 del/L858R w/ or w/out EGFR T790M, TP53, EML4-ALK and BIM mRNA expression Rosell R, MD, PhD

[volver]

American Society of Clinical Oncology (ASCO) Annual Meeting

FECHA01/06/2012 - 05/06/2012

LUGAR DE REALIZACIÓNChicago, U.S.A.

EFGR compound mutants discriminate survival to erlotinibin non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study Rosell R, MD, PhD

Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small-cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay Benlloch S, PhD

[volver]

Metastatic Melanoma - Oncogenic lesions and dysregulation of canonical signaling pathways – clinical intervention

FECHA26/04/2012

LUGAR DE REALIZACIÓNUSP Hospital Dexeus, Barcelona, Spain

Oncogenic driver mutations in melanoma and other tumors: new opportunities for combinatory therapies Rosell R, MD, PhD

Is there still room for chemotherapy in lung cancer? Lessons from EGFR-driven cancer González Cao M, MD

BRAF mutations in cfDNA in blood: lessons from EGFR mutations in cfDNA Molina M.D, PhD

Programa

[volver]